| 產(chǎn)品詳情 |
| Edit |   |
|---|
| Product Name | ABT-869 |
|---|
| Description | ABT-869 is multi-targeted inhibitor of all members of the VEGF and PDGF receptor families (e.g., KDR, IC50 value of 4 nM), but has much less activity (IC50 values >1 μM) against unrelated receptor tyrosine kinases, soluble tyrosine kinases or serine/threonine kinases. The kinase inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 values of 2, 4 and 7 nM for PDGFRβ, KDR and CSF-1R, respectively) and VEGF-stimulated proliferation (0.2 nM IC50 for human endothelial cells). MW: 375.41. Purity ≥99% |
|---|
| Size | 1 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Linifanib |
|---|
| Gene, Accession, CAS # | CAS: 796967-16-3 |
|---|
| Catalog # | 1615-1 |
|---|
| Price | |
|---|
| Order / More Info | ABT-869 from BIOVISION, INC. |
|---|
| Product Specific References | n/a |
|---|
| 產(chǎn)品資料 |
|
|